IFNB1 and COVID-19: Thus, by replenishing MS immune system with IFN-regulated functions, IFN-β therapy, alone or in continuous or cyclic combination regimen with other drugs (2, 23), may represent a treatment that combines safety and efficacy in the COVID-19 era.